WHO WE ARE

ABOUT

Roivant’s mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the healthcare system. We are a unique biopharmaceutical company with world-class drug development experts working across multiple clinical and functional areas.

 

OUR WORK

PIPELINE

Roivant Sciences builds its pipeline through strategic alliances, collaborations and partnerships with academic institutions and other pharmaceutical companies. Our company has several ongoing late-stage clinical development programs spanning multiple indications and technologies.

THERAPEUTIC AREA
COMPOUND
INDICATION
PHASE
therapeutic area Compound Indication Phase 1 Phase 2 Phase 3
NEUROSCIENCE / DEMENTIA INTEPIRDINE

Mild-to-Moderate Alzheimer's Disease

3

Dementia with Lewy Bodies (DLB)

3

Gait and Balance Impairments in Dementia

2

NELOTANSERIN

Visual Hallucinations in Lewy Body Dementia

2

REM Behavior Disorder (RBD) in DLB

3

RVT-103 and RVT-104

Alzheimer's Disease

1

Lewy Body Dementia

1

ENDOCRINOLOGY RELUGOLIX

Uterine Fibroids

3

Endometriosis

3

RVT-602

Female Infertility

2

ONCOLOGY RELUGOLIX

Prostate Cancer

3

RARE DISEASES RVT-801

Farber Disease

2

DERMATOLOGY RVT-501

Mild-to-Moderate Atopic Dermatitis

3

RVT-201

Mild-to-Moderate Atopic Dermatitis

2

OTHER RVT-701

Autism

2

OUR FOCUS

THERAPEUTIC AREAS

Roivant Sciences has a special interest in the following disease categories, where we have deep in-house expertise:

OUR PEOPLE

LEADERSHIP

Members of our development team have achieved FDA approval for 7 New Drug Applications on industry-beating timelines, including blockbuster products such as Aricept®, Aciphex®, and Sovaldi®.

Our directors have deep experience in pharmaceutical business development, as well as life sciences and quantitative investing.

WHO WE WORK WITH

PARTNERS

Roivant Sciences has strategic alliances with partners who share our patient-centric commitment to develop promising drug candidates into approved medicines. Our company delivers R&D solutions to our biopharmaceutical industry partners, enabling them to unlock value from their pipelines and scale their businesses.

Roivant seeks late-stage drug candidates with the potential for accelerated regulatory approval timelines, where our significant capital base and world-class development expertise can maximize the opportunity for these drugs to positively impact the lives of patients. Our company will selectively evaluate regional or global product opportunities across all therapeutic areas, mechanisms of action, routes of administration, and levels of innovativeness.

Takeda logo
Eisai
GSK
Vertex
Arena
DukeMedicine_Logo
dexcel
cincinnati-childrens-hospital-medical-center-01
Arbutus
PlexceraLogo_Gradient_Col_CMYK
Axovant
6x1_myovant_colorlogo_72dpi
enzyvant_large_transparent_background

GET IN TOUCH

CONTACT US

Roivant Sciences Ltd.
Clarendon House
2 Church Street
Hamilton HM 11
Bermuda

Roivant Sciences Ltd.
Park Place
55 Par-La-Ville Road
2nd Floor
Hamilton HM 11
Bermuda

Roivant Sciences, Inc.
320 West 37th Street
5th Floor
New York, NY 10018
United States

Roivant Sciences, Inc.
302 E. Pettigrew St.
Suite PZ220
Durham, NC 27701
United States